We are at the forefront of innovation, adapting to shifting societal needs and turning scientific and technological advancements into transformational solutions for patients. In everything we do, we strive to make a positive impact on patients, society and the environment – now, and for generations to come.
Dr Severin Schwan
Chairman
Dr Thomas Schinecker
CEO Roche Group
Keeping patients at the heart of everything we do, our ambition is clear: to prevent, stop, and cure diseases, and, with that, improve outcomes and reduce costs for patients and healthcare systems worldwide.
Roche is uniquely positioned to lead the way for better healthcare with its Diagnostics and Pharmaceuticals under one roof.
Group sales:
CHF 60.495 million
Pharmaceuticals sales:
CHF 46.171 million
Diagnostics sales:
CHF 14.324 million
Core operating profit:
CHF 20.823 million
R&D core investments:
CHF 13.042 million
Dividend proposal:
CHF 9.70
*Unless otherwise stated, all growth rates and year-on-year comparisons are at constant exchange rates (CER; 2023 average) and all total figures are reported in Swiss francs.
Roche extended its partnership with City Cancer Challenge, committing to a new three-year partnership in a collaboration that reaches an estimated 66.5 million people.
in scope of our low- and lower-middle-income country (LLMIC) access goal used our core medicines in 2024, as we aim to double access from 27,000 patients in 2021 until 2026.
were treated with Roche medicines in 2024, compared to 37 countries in 2023 and 33 countries in 2021.
were approved or future approval was in progress in LLMICs in 2024, compared to 68% in 2023 and 60% in 2021.
delivered to our customers worldwide in 2024.
were screened for risk of cervical cancer using Roche’s HPV tests – around 740,000 in markets served by the Global Access Program, compared to 300,000 in 2023.
*Low-lower-middle-income countries (LLMICs)
Xolair
Alecensa
PiaSky
Tecentriq Hybreza (SC)
Ocrevus SC
Itovebi + palbociclib + fulvestrant
Tecentriq SC
Alecensa
Ocrevus SC
Vabysmo
PiaSky
PiaSky
Vabysmo
Alecensa
PiaSky
Vabysmo
CellCept
Alecensa
Evrysdi
Lunsumio
1 new platform
2 new tests
6 new tests
3 new platforms
10 new tests
1 new platform
3 new tests
2 new digital solutions
5 new digital solutions
The Head Corporate Strategy and Sustainability and Roche’s Chief Sustainability Officer, discussing the critical role of sustainability for future success – for Roche and society.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.